Patents Represented by Attorney Albert P. Pennie & Edmonds Halluin
  • Patent number: 5522175
    Abstract: The present invention relates to the production of three (3) distinct savory flavor types of dehydrated mushrooms: (1) a light-colored material with strong mushroom flavor, (2) a tan-colored material with a meaty, buttery and savory flavor and (3) a dark-colored material with a beefy, meaty, chocolate flavor. All three products exhibit "umami" or monosodium glutamate (MSG)-like mouthfeel and flavor synergy. The mushrooms are produced using specialized nutrient additives, controlled growing conditions and specialized dehydration protocols.
    Type: Grant
    Filed: June 1, 1994
    Date of Patent: June 4, 1996
    Assignee: Biosource Technologies, Inc.
    Inventor: R. Barry Holtz
  • Patent number: 5521076
    Abstract: Genetically engineered or transduced hepatocytes which express genetic material of interest introduced or incorporated into them, as well as methods of producing, transplanting and using the genetically engineered hepatocytes are disclosed. The genetic material of interest can be incorporated through the use of a vector, such as a recombinant retrovirus, which contains the genetic material of interest, or by other means.
    Type: Grant
    Filed: October 22, 1992
    Date of Patent: May 28, 1996
    Assignees: Whitehead Institute For Biomedical Research, Howard Hughes Medical Center
    Inventors: Richard C. Mulligan, James M. Wilson
  • Patent number: 5519053
    Abstract: Unsubstituted or substituted 5-iodo-6-amino-1,2-benzopyrones and their metabolites are potent, selective and non-toxic inhibitors and supressants of cancer growth and viral infections in a mammalian host. The compounds are particularly useful for treatment and supression of tumors and viruses associated with AIDS, herpetic episodes and cytomegaloviral infections. The methods of treatment of tumorigenic and viral diseases by 5-iodo-6-amino-1,2-benzopryrones and/or its metabolites are described.
    Type: Grant
    Filed: February 24, 1993
    Date of Patent: May 21, 1996
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev
  • Patent number: 5512468
    Abstract: The invention provided herein includes gram negative bacteria cells containing a gene encoding an enzyme with carbohydrate degrading activity that had been rendered competent to transformation. Carbohydrate degrading enzymes of interest for use in the invention include alpha-amylase. The competent cells of the subject invention may be frozen so as to provide for prolonged storage.Other aspects of the invention include methods for rendering gram negative bacterial cells, such as E. coli cells competent to transformation. These methods involve the step of transferring a gene encoding an enzyme with carbohydrate degrading activity into E. coli cells and subsequently rendering the cells competent using any of a variety of competency inducing procedures.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: April 30, 1996
    Assignee: Stratagene
    Inventor: Alan L. Greener
  • Patent number: 5506137
    Abstract: Purified thermostable DNA ligase is described that catalyzes template-dependent ligation at temperatures of about 30.degree. C. to about 80.degree. C., and which substantially retains its catalytic ability when subjected to temperatures of from about 85.degree. C. to about 100.degree. C. The thermostable DNA ligase has an estimated molecular weight of 50,000 to 70,000 daltons. A preferred thermostable DNA ligase is described that was isolated from the archaebacteria Pyrococcus furiosus. Also described are plasmid vectors for producing recombinant thermostable DNA ligase.
    Type: Grant
    Filed: July 22, 1993
    Date of Patent: April 9, 1996
    Assignee: Stratagene
    Inventors: Eric J. Mathur, Edward J. Marsh, Warren E. Schoettlin
  • Patent number: 5500483
    Abstract: Two novel genomic clones, ZZA1 and ZZA2, were isolated which encode for Pichia pastoris alcohol oxidase isozymes. The 5' non-coding region of ZZA1 contains common structural features involved in the transcription and translation of eukaryotic genes. Comparison of the nucleotide sequences of the ZZA1 and AOX15' noncoding regions showed that they are 66% similar to each other.The rice .alpha.-amylase gene OS103 was placed under the transcriptional control of the ZZA1 promoter. The nucleotide sequences of ZZA1 and other methanol-regulated promoters were analyzed. A highly conserved sequence (TTGNNNGCTTCCAANNNNNTGGT) (SEQ ID NO: 2) was found in the 5' flanking region. A yeast strain containing the ZZA1-OS103 fusion and secreting biologically active .alpha.-amylase into the culture media while converting starch to ethanol was produced. The ZZA1 and ZZA2 regulatory sequences may be used to contol the expression of other heterologous proteins in multiple yeast species.
    Type: Grant
    Filed: March 25, 1993
    Date of Patent: March 19, 1996
    Assignee: Biosource Technologies, Inc.
    Inventors: Monto H. Kumagai, Genadie G. Sverlow
  • Patent number: 5496725
    Abstract: A gene, encoding an endocellulase from a newly isolated mesophilic Clostridium strain IY-2 which can digest bamboo fibers, cellulose, rice straw, and sawdust, was isolated by shotgun cloning in an E. coli expression plasmid pLC2833. E. coli positive clones were selected based on their ability to hydrolyze milled bamboo fibers and cellulose present in agar plates. One clone contained a 2.8 kb DNA fragment that was responsible for cellulase activity. Western blot analyses indicated that the positive clone produced a secreted cellulase with a mass of about 58,000 daltons that was identical in size to the subunit of one of the three major Clostridium cellulases. The products of cellulose digestion by this cloned cellulase were cellotetraose and soluble higher polymers. The cloned DNA contained signal sequences capable of directing the secretion of heterologous proteins from an E. coli host.
    Type: Grant
    Filed: August 11, 1993
    Date of Patent: March 5, 1996
    Inventor: Ida K. Yu
  • Patent number: 5491062
    Abstract: The invention described herein consists of methods and materials for the detection of mycoplasma infections. Mycoplasma infections may be detected in cell cultures and in animals. The subject methods use polynucleotide primer pairs that are capable of hybridizing to mycoplasma tRNA genes so as to provide for the generation of a distinctive set of amplification products when the primers are used in a cyclic amplification synthesis reaction, such as PCR (polymerase chain reaction). In addition to detecting mycoplasma infections, the subject methods may be used to identify the particular species of mycoplasma causing the infection. The subject invention also provides for primers and kits for performing the subject methods.
    Type: Grant
    Filed: November 23, 1993
    Date of Patent: February 13, 1996
    Assignee: Stratagene
    Inventors: Douglas T. McKenzie, Joseph A. Sorge
  • Patent number: 5489523
    Abstract: A recombinant thermostable Pyrococcus furiosus DNA polymerase is described that is deficient in 3'-5' exonuclease activity that is useful in DNA cycle sequencing reactions.
    Type: Grant
    Filed: October 26, 1992
    Date of Patent: February 6, 1996
    Assignee: Stratagene
    Inventor: Eric J. Mathur
  • Patent number: 5486351
    Abstract: A process for the in vitro production of chemically modified polyphenolic polymer (PPP). First, stable, highly active extracellular tyrosinase is produced from genetically transformed microorganism such as Streptomyces antibioticus. The tyrosinase is then incubated with a reaction substrate such as 1-tyrosine, hydrolyzed protein, or an oligopeptide in combination with 1-tyrosine. The ratio of the oligopeptide/tyrosine combination as well as variation in the concentration of tyrosinase can be used to modify the color, the molecular size, and the spectral absorbance properties of the PPP produced. Alternatively, or additionally, oxidants such as hydrogen peroxide or hypochlorite can be used to modify the color of the PPP, regardless of the method used to produce the PPP, and the PPP can subsequently be fractionated using molecular weight cut-off ultrafiltration. Organic solvents can also be used in the method of making PPP to produce PPPs having variable but reproducible physical properties.
    Type: Grant
    Filed: December 14, 1993
    Date of Patent: January 23, 1996
    Assignee: Biosource Technologies, Inc.
    Inventors: Guy R. della-Cioppa, Stephen J. Garger, Jr., Richard B. Holtz, Michael J. McCulloch, Genadie G. Sverlow
  • Patent number: 5478731
    Abstract: A bacteriophage packaging site-based vector system is describe that involves cloning vectors and methods for their use in preparing multiple copy number bacteriophage libraries of cloned DNA. The vector is based on a DNA segment that comprises a nucleotide sequence defining a bacteriophage packaging site located between two termini having ligation means used to concatamerize fragments of DNA having compatible ligation means. Methods for preparing a concatameric DNA for packaging cloned DNA segments, and for packaging the concatamers to produce a library are also described.
    Type: Grant
    Filed: October 12, 1993
    Date of Patent: December 26, 1995
    Assignee: Stratagene
    Inventor: Jay M. Short
  • Patent number: 5472582
    Abstract: The present invention provides for the use of the fluorescent label 2-aminoacridone for use in separating carbohydrate mixtures and analyzing the structure of carbohydrates. Carbohydrates for analysis may be labeled by 2-aminoacridone and subsequently separated from one another by electrophoresis. The electrophoresis may be in one or two dimensions. Band produced by the electrophoresis may be visualized and quantitated directly by UV illumination or by means of a charge coupled device for photoelectric detection. 2-aminoacridone labelling of carbohydrate may also be used to analyze the structure of carbohydrates by cleaving (or adding to) various 2-aminoacridone labeled carbohydrates by carbohydrate modifying enzymes of known specificity, and subsequently separating the carbohydrates by electrophoresis in either one or two dimensions. The subject invention also provides for kits for performing 2-aminoacridone labelling and electrophoresis.
    Type: Grant
    Filed: July 9, 1993
    Date of Patent: December 5, 1995
    Assignee: Astromed Limited
    Inventor: Peter Jackson
  • Patent number: 5466592
    Abstract: A process for the in vitro production of chemically modified polyphenolic polymer (PPP). First, stable, highly active extracellular tyrosinase is produced from genetically transformed microorganism such as Streptomyces antibioticus. The tyrosinase is then incubated with a reaction substrate such as l-tyrosine, hydrolyzed protein, or an oligopeptide in combination with l-tyrosine. The ratio of the oligopeptide/tyrosine combination as well as variation in the concentration of tyrosinase can be used to modify the color, the molecular size, and the spectral absorbance properties of the PPP produced. Alternatively, or additionally, oxidants such as hydrogen peroxide or hypochlorite can be used to modify the color of the PPP, regardless of the method used to produce the PPP, and the PPP can subsequently be fractionated using molecular weight cut-off ultrafiltration. Organic solvents can also be used in the method of making PPP to produce PPPs having variable but reproducible physical properties.
    Type: Grant
    Filed: November 17, 1993
    Date of Patent: November 14, 1995
    Assignee: Biosource Technologies, Inc.
    Inventors: Guy R. della-Cioppa, Stephen J. Garger, Jr., Richard B. Holtz, Michael J. McCulloch, Genadie G. Sverlow
  • Patent number: 5464871
    Abstract: Unsubstituted or substituted halo nitro and nitroso compounds and their metabolites are potent, selective and non-toxic inhibitors and supressants of cancer growth and viral infections in a mammalian host. The compounds are particularly useful for treatment and supression of tumors and viruses associated with breast cancer, AIDS, herpetic episodes and cytomegaloviral infections. The methods of treatment of tumorigenic and viral diseases by halo nitro nitroso compounds and their metabolites are described.
    Type: Grant
    Filed: June 11, 1993
    Date of Patent: November 7, 1995
    Assignee: Octamer, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev, Eva Kirsten
  • Patent number: 5460959
    Abstract: Fibroblasts transduced with genetic material encoding a polypeptide or protein of interest and, optionally, a selectable marker, as well as methods for making and using the transduced fibroblasts. Such fibroblasts are useful in delivering the encoded polypeptide or protein, such as an enzyme, a hormone or a drug, to an individual who has had a graft or implant of the transduced cells.
    Type: Grant
    Filed: June 1, 1993
    Date of Patent: October 24, 1995
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Richard C. Mulligan, James M. Wilson
  • Patent number: 5451572
    Abstract: A pharmaceutical composition is provided wherein human relaxin is formulated at an acidic pH of about 4 to less than about 7. The composition, useful for effecting parturition and inhibiting premature delivery, includes a buffer capable of maintaining the pH of the composition within a desired range, and may also include an agent to make the composition isotonic, and a stabilizing agent, if necessary. A specific example is human relaxin formulated in a citrate buffer, pH about 5.0, in the presence of sodium chloride, at an ionic strength of about 0.15 .mu..
    Type: Grant
    Filed: April 20, 1993
    Date of Patent: September 19, 1995
    Assignee: Genentech, Inc.
    Inventors: David C. Cipolla, Tue H. Nguyen, Steven J. Shire
  • Patent number: 5449614
    Abstract: Packaging cell lines useful for the generation of helper-free recombinant retroviruses with amphotropic or ecotropic host ranges, methods of constructing such packaging cell lines and methods of using the recombinant retroviruses to introduce DNA of interest into eukaryotic cells, both in vitro and in vivo.
    Type: Grant
    Filed: February 22, 1994
    Date of Patent: September 12, 1995
    Assignee: Whitehead Institue For Biomedical Research
    Inventors: Olivier Danos, Richard C. Mulligan